Medical Patent News

RSS

EPO to grant patent for Apricus MycoVa product to treat nail fungus

Apricus Biosciences, Inc. announced today that the European Patent Office will grant a patent for the company's MycoVa product for treating onychomycosis.

2 Mar 2011

EPO cancels PDL's '216B European Patent

PDL BioPharma, Inc. announced today that the Technical Board of Appeal of the European Patent Office has cancelled its hearing in which three appellants sought to have a 2007 decision upholding PDL's European Patent No. 0 451 216B overturned and the patent revoked.

1 Mar 2011

Cummings School granted U.S. Patent for antibody-based treatment against Hemolytic Uremic Syndrome

Researchers at the Cummings School of Veterinary Medicine have received U.S. patent approval for an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially fatal outcome of E. coli poisoning and the leading cause of kidney failure in children.

1 Mar 2011

EPO grants three core patents to caprotec's CCMS technology

caprotec bioanalytics GmbH announced today that the European Patent Office has granted the last of three core patents protecting its proprietary and revolutionary Capture Compound Mass Spectrometry technology.

28 Feb 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

U.S. District Court rules in favor of Hologic in breast brachytherapy patent infringement lawsuit

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the United States Court of Appeals for the Federal Circuit has ruled in favor of Hologic, by reversing the previous decisions reached by the United States District Court for the Northern District of California, in favor of SenoRx, Inc.

From Hologic, Inc. 28 Feb 2011

Aerocrine announces positive outcome of its patent proceedings against Medisoft

Aerocrine AB today announced the positive outcome of its patent proceedings against Medisoft P.A.E. at the Court of Appeal of Dusseldorf and the Federal Patent Court of Munich.

25 Feb 2011

Celgene, Elan enter settlement and license agreement for ABRAXANE

Elan Corporation plc and Celgene Corporation, today announced that Elan subsidiary Elan PharmaInternational Limited has entered into a settlement and license agreement with Celgene Corporation resolving the patent infringement litigation involving ABRAXANE.

24 Feb 2011

ACT receives patent for its single-blastomere technology

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent on its "single-blastomere" technique. Patent Number 7,893,315 broadly covers ACT's proprietary single-blastomere technology that provides a non-destructive alternative for deriving human embryonic stem cell lines.

23 Feb 2011

Diabetes technology granted patent in Australia

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant therapy to treat diabetes and neurodegenerative diseases, has been granted a patent by the Australian Patent Office for IMMUPEL(tm), LCT's industry-leading technology for encapsulating living cells prior to transplantation.

23 Feb 2011

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.

23 Feb 2011

USPTO issues patent to Silence Therapeutics' siRNA technology

Silence Therapeutics plc announces the issuance of United States patent 7,893,245, titled "Interfering RNA Molecules," by the United States Patent and Trademark Office.

23 Feb 2011

Noven claims patent infringement over Vivelle-Dot, files lawsuit against Mylan

Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Mylan Technologies Inc. ("Mylan") claiming infringement of certain Noven patents (the "Patents") by Mylan.

23 Feb 2011

USPTO issues Notice of Allowance to Somaxon's Silenor patent application

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for claims in U.S. patent application no. 11/781,165.

23 Feb 2011

Canadian Intellectual Property Office grants patent to CardioGenics' QL Care Analyzer

CardioGenics Holdings Inc. announced today that it has been notified by the Canadian Intellectual Property Office that its patent application for the "core technology" utilized in its ultra-sensitive point-of-care immuno-analyzer, the QL Care Analyzer, has been granted. Patents covering the "core technology" have now been issued in Canada, the European Union and Japan.

22 Feb 2011

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

VIRxSYS Corporation, a privately-held biotechnology company with proprietary RNA payload and lentiviral vector delivery platform technologies, today announced that the United States Patent and Trademark Office has issued the Company two patents for its SMaRT RNA platform technology, capable of reprogramming or repairing genes to create, increase or change protein expression.

18 Feb 2011

China-Biotics applies 5 new patents for probiotics supplement, preparation

China-Biotics, Inc., the leading developer, manufacturer and distributor of probiotics products in China, today announced it has applied for 5 new patents through its wholly owned subsidiary Growing Bioengineering to the State Bureau of Intellectual Property.

18 Feb 2011

Entellus Medical enters license agreement with Acclarent to resolve patent lawsuit

Entellus Medical today announced that it has entered into a licensing agreement with Acclarent, Inc. in order to resolve their patent lawsuit. The license agreement is royalty bearing to Acclarent.

18 Feb 2011

Benitec strengthens patent position in RNAi

Benitec Limited (ASX: BLT), (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, is pleased to announce that the United States Patent and Trademark Office (USPTO) has today indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO’s confirmation of patentability of claims in the key ‘099 Graham Patent [US Patent No. 6,573,099] "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene", the wide-ranging platform technology patent covering the use of expressed RNA interference (RNAi) in human therapeutic applications.

17 Feb 2011

ACEA Biosciences receives new U. S. Patent for chemical compound screening

ACEA Biosciences, a pioneer in the development of high-performance microelectronic systems for cell-based assays, diagnostics, and pharmaceutical research, is pleased to report the issuance of a new U. S. Patent for chemical compound screening, with important applications in the development of new pharmaceutical products.

17 Feb 2011